Trial watch : Progress for Phase III cancer vaccines

  • B A Briefs
  • Published 2008 in Nature Reviews Drug Discovery

Abstract

Non-Hodgkin’s lymphoma. Biovest international has recently reported that data from a randomized, controlled Phase iii trial show that the cancer vaccine BiovaxiD significantly prolongs cancer-free survival for patients with follicular non-Hodgkin’s lymphoma. The intent-to-treat analysis (n = 117) showed a median duration of 44.2 months cancer-free survival… (More)
DOI: 10.1038/nrd2766

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.